A 5' UTR CCG expansion in TBC1D7 causes oculopharyngodistal myopathy

This study identifies heterozygous CCG repeat expansions in the 5' UTR of the TBC1D7 gene as a novel cause of oculopharyngodistal myopathy (OPDM) in European and mixed-ancestry families, revealing a dominant toxic gain-of-function mechanism and reinforcing the importance of noncoding repeat expansions in neuromuscular disease.

The Gist

The Big Picture: Finding a New "Broken Switch" in the Muscle Factory

Imagine your body's muscles are like a massive, complex factory. For the factory to run smoothly, it needs a perfect instruction manual (DNA). Sometimes, a typo in that manual causes the factory to break down, leading to muscle weakness.

For a long time, scientists knew about a specific type of typo called a CCG expansion. Think of this like a stutter in a song where a musician keeps repeating the same three notes ("C-C-C, C-C-C, C-C-C...") over and over again. If they repeat it too many times, the song gets stuck, the rhythm breaks, and the factory (the muscle) stops working.

This paper reports the discovery of a new location where this "stutter" happens. It was found in a gene called TBC1D7. Before this study, scientists knew of six other places where this stutter caused a rare muscle disease called Oculopharyngodistal Myopathy (OPDM). This new discovery adds TBC1D7 as the seventh known culprit.

What is OPDM? (The Symptoms)

OPDM is a disease that makes specific parts of the body weak:

• Eyes: Droopy eyelids (ptosis) and trouble moving eyes.
• Throat: Trouble swallowing (dysphagia) and speaking.
• Limbs: Weakness in the hands and feet (distal muscles).

It's like a power outage that hits the "control room" (eyes/throat) and the "delivery trucks" (hands/feet) first, while the main engine (core muscles) stays running for a while.

How Did They Find It? (The Detective Work)

The researchers acted like genetic detectives. They had three families with OPDM symptoms, but standard tests couldn't find the cause.

1. The Long-Read Telescope: They used a special type of DNA sequencing (Long-Read Sequencing) that acts like a high-powered telescope. Standard tests are like looking at a map from far away; you see the cities but miss the tiny details. This new "telescope" let them zoom in and see the long, repetitive "stutters" that other tests missed.
2. The Outlier Hunt: They also looked at a massive database of 100,000 genomes (the "Genomics England" project). They used a computer program to find the "odd ones out"—people with muscle disease who had unusually long repeats in the TBC1D7 gene compared to healthy people.

The Discovery: They found that in these families, the TBC1D7 gene had a stutter ranging from 83 to 148 repeats. Healthy people usually have fewer than 20.

The Mystery of the "Silent Carrier"

One of the most interesting parts of the study involves a father (let's call him "Dad C") who carried the huge stutter (184 repeats) but never got sick. His daughter, however, had a slightly smaller stutter (137 repeats) and was very sick.

Why? The answer lies in Methylation (think of this as a "mute button" or a "sticky note" on the gene).

• In the sick daughter: The stutter was "unmuted." The cell read the stuttery instructions, made a toxic protein, and the muscle broke down.
• In the healthy father: The stutter was "muted" (methylated). The cell put a sticky note over the gene saying, "Ignore this part." Because the gene was silenced, the toxic protein wasn't made, and he stayed healthy.

This is a crucial finding: Having the bad gene doesn't always mean you get sick. Sometimes, the body's "mute button" saves you.

What Happens Inside the Muscle?

When the gene is "unmuted," the cell tries to read the stuttery code.

• The Toxic Glue: The cell accidentally turns the stutter into a weird, sticky protein (polyglycine).
• The Clogs: These sticky proteins clump together inside the muscle cells, forming "trash piles" (inclusions) that clog the machinery.
• The Result: The muscle fibers get damaged, die, and are replaced by fat and scar tissue (seen in the MRI scans as "fatty degeneration").

Why Does This Matter?

1. New Diagnosis: Now, if a patient has OPDM symptoms but tests negative for the other six known genes, doctors can test for this new TBC1D7 stutter. This helps more families get answers.
2. The "Range" Theory: Scientists used to think there was a strict "safe limit" for repeats (e.g., anything over 100 is bad). This study shows it's more like a danger zone. Some people with 180 repeats are fine (because of the mute button), while others with 83 are very sick. It's not just about the number; it's about whether the gene is active or silenced.
3. A New Rule for Genetics: This study reinforces a new idea in genetics: The most dangerous genes aren't always the ones that are "broken" in a simple way. Sometimes, the most dangerous spots are the ones that are naturally wobbly and unstable in the general population, waiting to expand into a disease-causing length.

Summary

This paper is like finding a new leak in the ship's hull. The researchers found that a stutter in the TBC1D7 gene causes a specific muscle disease. They discovered that the severity of the disease depends not just on how big the stutter is, but on whether the body has "muted" the gene. This helps doctors diagnose more patients and understand that in the world of genetic diseases, the "volume" of the gene matters just as much as the "size" of the error.

Technical Summary

1. Problem Statement

Oculopharyngodistal myopathy (OPDM) is a rare, hereditary muscle disease characterized by ptosis, external ophthalmoplegia, and weakness in facial, pharyngeal, and distal limb muscles. Histologically, it is defined by rimmed vacuoles and intranuclear inclusions.

• Current Knowledge: Six genes (LRP12, GIPC1, NOTCH2NLC, RILPL1, ABCD3, LOC642361) have been identified as causes of OPDM, all linked to heterozygous CCG-CGG repeat expansions in their 5' untranslated regions (UTRs).
• The Gap: Most known OPDM genes were identified in Asian populations. Only ABCD3 had been reported in European ancestry. Despite these discoveries, a significant number of OPDM cases remain genetically unsolved, suggesting undiscovered loci with similar repeat motifs.
• Objective: To identify the genetic cause of OPDM in families of European and mixed African-European descent using advanced genomic sequencing.

2. Methodology

The study employed a multi-modal approach combining family-based sequencing, large-scale cohort analysis, and functional validation:

• Patient Cohort: Three unrelated families (Families A, B, and C) comprising seven affected individuals were recruited from centers in Belgium, the UK, and other European countries.
• Sequencing Technologies:
  • Short-Read WGS (srWGS): Analyzed 371 myopathy cases and 35,376 controls from the Genomics England 100,000 Genomes Project using ExpansionHunter denovo (EHdn) to detect repeat expansions.
  • Long-Read WGS (lrWGS): Used PacBio HiFi and Oxford Nanopore Technologies (ONT) sequencing on patient DNA (blood and muscle biopsy) to precisely size repeats and determine methylation status.
  • Optical Genome Mapping (OGM): Used for orthogonal validation of structural variants.
• Validation & Screening:
  • Repeat-Primed PCR (RP-PCR): Used to confirm segregation in families and screen an additional cohort of 27 OPDM patients.
  • Control Population Analysis: Genotyped the TBC1D7 locus in 1,020 ONT datasets from the 1000 Genomes Project to establish a baseline for normal variation.
• Functional Assays:
  • qPCR: Measured TBC1D7 transcript levels in patient-derived fibroblasts.
  • Histopathology: Muscle biopsies were stained for H&E, Gomori trichrome, and p62 to identify rimmed vacuoles and intranuclear inclusions.
  • Methylation Profiling: ONT sequencing was used to assess CpG methylation at the repeat locus.

3. Key Contributions

• Discovery of a Novel Gene: Identified TBC1D7 as a new gene causing OPDM, expanding the genetic architecture of the disease to include a seventh locus.
• Definition of Pathogenic Range: Established a pathogenic repeat size range of 83–148 CCG units for TBC1D7, distinguishing it from the highly variable but non-pathogenic alleles found in the general population.
• Mechanistic Insight into Non-Penetrance: Demonstrated that DNA methylation of the expanded repeat acts as a disease modifier. An unaffected carrier with a large expansion (184 repeats) showed full methylation (silencing the gene), whereas affected individuals with similar or smaller expansions were unmethylated.
• Haplotype Analysis: Revealed that the pathogenic expansion occurs on a shared ancestral haplotype, suggesting a common origin for the mutation in these families.
• Paradigm Shift: Reinforced the concept that pathogenicity in repeat expansion disorders is driven by sequence motif and genomic context (high variability) rather than the specific function of the host gene.

4. Key Results

Genetic Findings

• Identification: A heterozygous CCG expansion in the 5' UTR of TBC1D7 (chr6:13328476-13328603) was found in all three families.
• Repeat Sizes:
  • Affected individuals: Median repeat lengths ranged from 83 to 148 CCG units.
  • Unaffected carrier (Family C): Carried a larger expansion (184 CCG units) but was asymptomatic.
• Control Population: In the 1000 Genomes dataset, TBC1D7 showed extreme variability. Most alleles contained interrupted motifs (CCGCTG), while pure CCG stretches were rare and short (median 9 units). Expansions >50 repeats were extremely rare (0.1%) in controls.
• Segregation: The expansion segregated with the disease in Families A and B. In Family C, the expansion was paternally inherited.

Clinical & Histopathological Features

• Phenotype: Patients presented with classic OPDM features: ptosis, ophthalmoparesis, facial weakness, dysphagia, and distal limb weakness.
• Heterogeneity:
  • Age of Onset: Variable, ranging from the 2nd decade (Families B & C) to the 4th/5th decade (Family A).
  • Severity: Family B showed aggressive progression with early loss of ambulation, respiratory failure, and need for PEG/ventilation.
• Biopsy Findings: Muscle biopsies showed rimmed vacuoles and rare p62-positive intranuclear inclusions, consistent with other OPDM types.
• Biomarkers: Mild to moderately elevated Creatine Kinase (CK) levels and myopathic changes on EMG.

Molecular Mechanisms

• Expression: Patient fibroblasts showed significantly increased TBC1D7 transcript levels compared to controls, suggesting a toxic gain-of-function mechanism (RNA or protein toxicity).
• Methylation & Penetrance:
  • Affected (Unmethylated): The expanded allele was unmethylated in affected individuals, allowing transcription and likely leading to toxic accumulation.
  • Unaffected (Methylated): The unaffected carrier (C:I:1) with the largest expansion (184 repeats) showed hypermethylation of the repeat and flanking promoter, likely silencing the gene and preventing toxicity.
• Instability: The locus showed somatic instability (variability in repeat length between reads) and germline instability (both expansion and contraction observed during paternal transmission).

5. Significance

• Diagnostic Impact: This discovery provides a genetic test for previously unsolved OPDM cases, particularly in European and mixed-ancestry populations. It highlights the need to screen for CCG expansions in TBC1D7 in patients with partial OPDM phenotypes.
• Methodological Advance: The study underscores the necessity of long-read sequencing to resolve complex repeat structures, determine exact repeat counts, and assess methylation status, which short-read sequencing often misses.
• Theoretical Framework:
  • It supports a "pathogenic range" model rather than a strict threshold, where the lower bound is defined by toxicity and the upper bound by methylation-induced silencing.
  • It reinforces that highly polymorphic tandem repeats in the general population are the "hotspots" for pathogenic expansion, shifting the focus from gene function to repeat instability.
• Therapeutic Implications: The identification of a toxic gain-of-function mechanism (similar to NOTCH2NLC and GIPC1) suggests that therapeutic strategies targeting RNA toxicity or protein aggregation (e.g., antisense oligonucleotides) could be applicable to TBC1D7-related myopathy.

In conclusion, this paper establishes TBC1D7 as a major cause of OPDM, elucidates the complex interplay between repeat size, methylation, and penetrance, and provides a robust framework for discovering future repeat expansion disorders.